These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 34251288)

  • 21. Antiplatelet Therapy in Elderly Patients with Acute Coronary Syndromes: the Clopidogrel Revenge: Possible Reasons for a Bright Comeback.
    De Servi S; Landi A; Savonitto S
    Cardiovasc Drugs Ther; 2021 Apr; 35(2):399-401. PubMed ID: 32809109
    [No Abstract]   [Full Text] [Related]  

  • 22. Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors.
    Winter MP; Grove EL; De Caterina R; Gorog DA; Ahrens I; Geisler T; Gurbel PA; Tantry U; Navarese EP; Siller-Matula JM
    Eur Heart J Cardiovasc Pharmacother; 2017 Oct; 3(4):221-234. PubMed ID: 28204303
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prospective
    Tuteja S; Glick H; Matthai W; Nachamkin I; Nathan A; Monono K; Carcuffe C; Maslowski K; Chang G; Kobayashi T; Anwaruddin S; Hirshfeld J; Wilensky RL; Herrmann HC; Kolansky DM; Rader DJ; Giri J
    Circ Genom Precis Med; 2020 Feb; 13(1):e002640. PubMed ID: 31928229
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical outcomes of CYP2C19 genotype-guided antiplatelet therapy: existing evidence and future directions.
    Klein MD; Lee CR; Stouffer GA
    Pharmacogenomics; 2018 Aug; 19(13):1039-1046. PubMed ID: 30028231
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of CYP2C19-guided antiplatelet therapy for acute coronary syndromes in Singapore.
    Kim JH; Tan DS; Chan MYY
    Pharmacogenomics J; 2021 Apr; 21(2):243-250. PubMed ID: 33462345
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Advances in the Pharmacogenomics of Antiplatelet Therapy.
    Akhtar T; Bandyopadhyay D; Ghosh RK; Aronow WS; Lavie CJ; Yadav N
    Am J Ther; 2020; 27(5):e477-e484. PubMed ID: 31498157
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genotyping, Platelet Activation, and Cardiovascular Outcome in Patients after Percutaneous Coronary Intervention: Two Pieces of the Puzzle of Clopidogrel Resistance.
    Siasos G; Oikonomou E; Vavuranakis M; Kokkou E; Mourouzis K; Tsalamandris S; Zaromitidou M; Kioufis S; Tsigkou V; Deftereos S; Stefanadis C; Tousoulis D
    Cardiology; 2017; 137(2):104-113. PubMed ID: 28329746
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of point-of-care testing for CYP2C19 on platelet inhibition in patients with acute coronary syndrome and early dual antiplatelet therapy in the emergency setting.
    Stimpfle F; Karathanos A; Droppa M; Metzger J; Rath D; Müller K; Tavlaki E; Schäffeler E; Winter S; Schwab M; Gawaz M; Geisler T
    Thromb Res; 2014 Jul; 134(1):105-10. PubMed ID: 24856643
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of CYP2C19 genetic testing on provider prescribing patterns for antiplatelet therapy after acute coronary syndromes and percutaneous coronary intervention.
    Desai NR; Canestaro WJ; Kyrychenko P; Chaplin D; Martell LA; Brennan T; Matlin OS; Choudhry NK
    Circ Cardiovasc Qual Outcomes; 2013 Nov; 6(6):694-9. PubMed ID: 24192573
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genotype-guided antiplatelet therapy compared with conventional therapy for patients with acute coronary syndromes: a systematic review and meta-analysis.
    Zheng L; Yang C; Xiang L; Hao Z
    Biomarkers; 2019 Sep; 24(6):517-523. PubMed ID: 31215825
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CYP2C19 genotype-directed P
    Stys TP; Gedela M; Gowda SN; Bares V; Fanta L; Petrasko M; Hajek C; Larson E; Stys AT
    Indian Heart J; 2021; 73(3):281-288. PubMed ID: 34154743
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of P2Y12 Receptor Blockers After Myocardial Infarction and Genetic Variability of their Metabolic Pathways.
    Máchal J; Hlinomaz O
    Curr Vasc Pharmacol; 2019; 17(1):35-40. PubMed ID: 29412111
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacogenetic testing by polymorphic markers 681G>A and 636G>A CYP2C19 gene in patients with acute coronary syndrome and gastric ulcer in the Republic of Sakha (Yakutia).
    Fedorinov DS; Mirzaev KB; Ivashchenko DV; Temirbulatov II; Sychev DA; Maksimova NR; Chertovskih JV; Popova NV; Tayurskaya KS; Rudykh ZA
    Drug Metab Pers Ther; 2018 Jun; 33(2):91-98. PubMed ID: 29738309
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ticagrelor Versus Clopidogrel in Patients with Two CYP2C19 Loss-of-Function Alleles Undergoing Percutaneous Coronary Intervention.
    Xi Z; Zhou Y; Zhao Y; Liu X; Liang J; Chai M; Yu Y; Liu W
    Cardiovasc Drugs Ther; 2020 Apr; 34(2):179-188. PubMed ID: 32140798
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacogenomic Approach to Selecting Antiplatelet Therapy in Patients With Acute Coronary Syndromes: The PHARMCLO Trial.
    Notarangelo FM; Maglietta G; Bevilacqua P; Cereda M; Merlini PA; Villani GQ; Moruzzi P; Patrizi G; Malagoli Tagliazucchi G; Crocamo A; Guidorossi A; Pigazzani F; Nicosia E; Paoli G; Bianchessi M; Comelli MA; Caminiti C; Ardissino D
    J Am Coll Cardiol; 2018 May; 71(17):1869-1877. PubMed ID: 29540324
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness of
    Fu Y; Zhang XY; Qin SB; Nie XY; Shi LW; Shao H; Liu J
    Pharmacogenomics; 2020 Jan; 21(1):33-42. PubMed ID: 31849282
    [No Abstract]   [Full Text] [Related]  

  • 37. Latest evidence in personalized antiplatelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention.
    Uhry S; Bessereau J; Camoin-Jau L; Paganelli F; Bonello L
    Hosp Pract (1995); 2012 Apr; 40(2):104-17. PubMed ID: 22615085
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cytochrome P450 CYP 2C19*2 Associated with Adverse 1-Year Cardiovascular Events in Patients with Acute Coronary Syndrome.
    Wei YQ; Wang DG; Yang H; Cao H
    PLoS One; 2015; 10(7):e0132561. PubMed ID: 26147597
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clopidogrel response variability is associated with endothelial dysfunction in coronary artery disease patients receiving dual antiplatelet therapy.
    Siasos G; Oikonomou E; Zaromitidou M; Kioufis S; Kokkou E; Mourouzis K; Vlasis K; Vavuranakis M; Stone PH; Papavassiliou AG; Tousoulis D
    Atherosclerosis; 2015 Sep; 242(1):102-8. PubMed ID: 26188531
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genetic Determinants of P2Y
    Cavallari LH; Obeng AO
    Interv Cardiol Clin; 2017 Jan; 6(1):141-149. PubMed ID: 27886818
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.